Merger and acquisition activity is at a seven-year low in 2024 as buyers digest prior deals and US election jitters delayed further spending. Expect a pick-up in 2025.
Login or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Senior, M. Nat. Biotech. 42, 1331–1338 (2024).
Senior, M. Nat. Biotech. 42, 362–366 (2024).
Senior, M. Nat. Biotech. 42, 1003–1008 (2024).
Brantly, M. L. et al. Chronic Obstr Pulm Dis. 11, 282–292 (2024).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, M. Biopharma deals get smaller and earlier. Nat Biotechnol 43, 11–18 (2025). https://doi.org/10.1038/s41587-024-02506-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-024-02506-7
This article is cited by
-
Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next?
Nature Biotechnology (2025)
